LMR Master Fund’s Cascadian Therapeutics CASC Stock Holding History
Bought
Maintained
Sold
Other funds holding CASC
LMR Master Fund's CASC Position: Q4 2013 in Review
LMR Master Fund opened a new position in Cascadian Therapeutics (CASC) in Q4 2013: 4,184 shares worth $44K. The stake represents ﹤0.01% of the portfolio and ranks #337 among its holdings. This is a return to the name: LMR Master Fund previously reported a position in CASC as recently as Q2 2013.
LMR Master Fund first reported a position in CASC in Q2 2013 and has held it in 2 quarters since. The position peaked at $290K in Q2 2013. 67 funds tracked by Wall St. Rank hold CASC as of Q4 2013.
- LMR Master Fund held 4,184 shares of Cascadian Therapeutics worth $44K as of Q4 2013.
- Cascadian Therapeutics was a new LMR Master Fund position in Q4 2013.
- Cascadian Therapeutics made up ﹤0.01% of LMR Master Fund's portfolio in Q4 2013, its #337 holding.
- LMR Master Fund first reported a position in Cascadian Therapeutics in Q2 2013 and has held it in 2 quarters since.
- LMR Master Fund's Cascadian Therapeutics position peaked at $290K in Q2 2013.
- 67 funds tracked by Wall St. Rank held Cascadian Therapeutics as of Q4 2013.
Based on LMR Master Fund's 13F filing for Q4 2013, filed 14 Feb 2014.